---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054478"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:17:26.532367+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Q1 2024 net loss $10.9M; cash $72.8M; clinical trials on track

## Summary
- Net loss of $10.9M vs $6.4M in Q1 2023; R&D expense rose to $8.8M from $5.0M.
- Cash, equivalents and marketable securities $72.8M; runway expected into 2026.
- Phase 2a RIVER trial in RCC fully enrolled? all sites activated; topline data expected H2 2024.
- Phase 2b CORAL trial in IPF chronic cough enrolling ~160 pts; topline data H1 2025.
- HAP study 75% enrolled; IND cleared for Phase 1b respiratory physiology trial starting Q3 2024.

## SEC filing metadata
- accession: 0000950170-24-054478
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/0000950170-24-054478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/trvi-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054478
- JSON: https://secwatch.observer/filing/0000950170-24-054478.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054478.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.. Guidance reaffirmed.
  - Period: quarter ended March 31, 2024
  - Net income: Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.4 million in the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/0000950170-24-054478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.